Kathryn Parker, MD
Internal Medicine · Dardanelle, ARNPI 1285087429
Payments from drug & device makers
Across 86 payments — averaging $20.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$450
- Lilly USA, LLC$322
- Ironshore Pharmaceuticals Inc.$128
- UCB, Inc.$125
- Novo Nordisk$105
- GSK$81
- plus $546 from 19 others
What the payments were for
- Food & beverage$1,67695%
- Education$815%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 15 | $450 |
| Lilly USA, LLC | 28 | $322 |
| Ironshore Pharmaceuticals Inc. | 4 | $128 |
| UCB, Inc. | 1 | $125 |
| Novo Nordisk | 6 | $105 |
| GSK | 4 | $81 |
| Astellas Pharma US Inc | 1 | $69 |
| AstraZeneca | 4 | $60 |
| Amgen | 3 | $44 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $43 |
| Boehringer Ingelheim | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Pfizer | 2 | $34 |
| Verona Pharma, Inc. | 1 | $26 |
| Almatica Pharma LLC | 1 | $25 |
| Shield Therapeutics Inc | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Seqirus USA Inc | 1 | $19 |
| Nevro Corp. | 1 | $16 |
| Bayer | 1 | $15 |
| Exact Sciences | 1 | $15 |
| Bausch Health US, LLC | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
| Corium, LLC | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,757 in reported general payments places this provider in the 75th percentile of 614 internal medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 145 | $161,218 |
| FarxigaDapagliflozin Propanediol | 117 | $104,272 |
| JardianceEmpagliflozin | 83 | $83,371 |
| OzempicSemaglutide | 77 | $79,543 |
| EliquisApixaban | 88 | $73,365 |
| TrulicityDulaglutide | 52 | $50,812 |
| JanuviaSitagliptin Phosphate | 47 | $42,343 |
| XareltoRivaroxaban | 32 | $31,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $24,459 |
| MyrbetriqMirabegron | 19 | $12,565 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,783 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,603 |
| Arnuity ElliptaFluticasone Furoate | 17 | $7,955 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $7,080 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $5,741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $322 | $212,030197 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $60 | $119,657148 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $42 | $88,95594 claims |
| Novo NordiskOzempic | $105 | $79,54377 claims |
| PfizerEliquis | $34 | $73,36588 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $81 | $49,09886 claims |
| Astellas Pharma US IncMyrbetriq | $69 | $12,56519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 614 internal medicine providers in Arkansas.
Other internal medicine in Dardanelle
- Priyantha WijewardaneLittle Rock$43.6M
- Joseph RoseLittle Rock$1.1M
- David JohnsonSearcy$630K
- Kathleen GannonRogers$450K
- Alexander KaczenskiLittle Rock$305K
- John HendersonSearcy$102K
- David PyleJonesboro$93K
- Manisha SinghLittle Rock$71K
- Govinda LohaniN Little Rock$55K
- Srikanth VallurupalliLittle Rock$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.